An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Ferdinando D’Amico; Luca Massimino; Giulia Palmieri; Arianna Dal Buono; Roberto Gabbiadini; Bénédicte Caron; Paula Moreira; Isabel Silva; Marta Maia Boscá-Watts; Tommaso Innocenti; Gabriele Dragoni; Cristina Bezzio; Alessandra Zilli; Federica Furfaro; Simone Saibeni; María Chaparro; María José García; Giorgos D. Michalopoulos; Nikos Viazis; Gerassimos J. Mantzaris; Pierre Ellul; Javier P. Gisbert; Fernando Magro; Laurent Peyrin‐Biroulet; Alessandro Armuzzi; Federica Ungaro; Silvio Danese; Gionata Fiorino; Mariangela Allocca

doi:10.1111/eci.14283

Abstract

This is the authors' abstract. We don't add key points for this paper.

Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

D’Amico et al. (2024) studied this question.

synapsesocial.com/papers/68e60e42b6db6435875a0f48 https://doi.org/10.1111/eci.14283

View Full Paper

Ask AI

Bookmark

Share

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Abstract

Ask about this paper

Discussion

Cite This Study

An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading